BIIB

SEC source: 0001127602-22-004801 · form4.xml · derivative · entry 2

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,090

Underlying: Common Stock · 9,090 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004790 · form4.xml · derivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,770

Underlying: Common Stock · 9,770 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004784 · form4.xml · derivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,815

Underlying: Common Stock · 6,815 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004781 · form4.xml · derivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,545

Underlying: Common Stock · 4,545 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004775 · form4.xml · derivative · entry 2

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,405

Underlying: Common Stock · 28,405 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-001864 · form4.xml · nonDerivative · entry 1

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,064.131

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

F2 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.

SEC source: 0001127602-22-001863 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,027.6165

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

F2 · balance_after: Includes 71.5888 shares, 14,2341 shares, 10.4331 shares and .0001 share acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021, 6/30/2021, 9/30/2021 and 12/31/2021, respectively.

SEC source: 0001127602-22-001861 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,354.348

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

SEC source: 0001127602-22-001862 · form4.xml · nonDerivative · entry 1

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,007

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

SEC source: 0001127602-22-001859 · form4.xml · nonDerivative · entry 1

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,666.188

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

F2 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.

SEC source: 0001127602-22-001858 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,878

F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022.

SEC source: 0001127602-21-030720 · form4.xml · derivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,052

Underlying: Common Stock · 1,052 shares

Expires 2024-12-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021.

SEC source: 0001127602-21-030462 · form4.xml · derivative · entry 7

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 265 shares

Expires 2021-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-030462 · form4.xml · derivative · entry 6

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 104 shares

Expires 2021-12-03

F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-21-030462 · form4.xml · derivative · entry 5

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104

Underlying: Common Stock · 74 shares

Expires 2021-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 4

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,110.348

SEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,132.348

SEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,210.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-030351 · form4.xml · derivative · entry 4

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 858

Underlying: Common Stock · 484 shares

Expires 2022-12-02

F2 · kind: This number represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-21-030351 · form4.xml · derivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,342

Underlying: Common Stock · 372 shares

Expires 2022-12-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-21-030351 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,106

SEC source: 0001127602-21-030351 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-024863 · form4.xml · derivative · entry 7

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,728

Underlying: Common Stock · 2,038 shares

Expires 2023-09-01

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]).

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-21-024863 · form4.xml · derivative · entry 6

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,766

Underlying: Common Stock · 3,324 shares

Expires 2023-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]).

SEC source: 0001127602-21-024863 · form4.xml · derivative · entry 5

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,364

Underlying: Common Stock · 2,681 shares

Expires 2023-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 09/01/2020.

SEC source: 0001127602-21-024863 · form4.xml · nonDerivative · entry 4

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,423

SEC source: 0001127602-21-024863 · form4.xml · nonDerivative · entry 3

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-024863 · form4.xml · nonDerivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,540

SEC source: 0001127602-21-024863 · form4.xml · nonDerivative · entry 1

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,681

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-001858 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,053

SEC source: 0001127602-21-021351 · form4.xml · nonDerivative · entry 1

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,872

SEC source: 0001127602-21-021352 · form4.xml · nonDerivative · entry 1

DENNER ALEXANDER J · CIK 0001361754 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,729

SEC source: 0001127602-21-021346 · form4.xml · nonDerivative · entry 1

Rowinsky Eric K · CIK 0001318886 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,844

SEC source: 0001127602-21-021349 · form4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,103

SEC source: 0001127602-21-021343 · form4.xml · nonDerivative · entry 1

Posner Brian S · CIK 0001372455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,175

SEC source: 0001127602-21-021341 · form4.xml · nonDerivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,729

SEC source: 0001127602-21-021337 · form4.xml · nonDerivative · entry 1

Freire Maria C · CIK 0001547999 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775

SEC source: 0001127602-21-021340 · form4.xml · nonDerivative · entry 1

LEAMING NANCY · CIK 0001265751 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,763

SEC source: 0001127602-21-021336 · form4.xml · nonDerivative · entry 1

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,840

SEC source: 0001127602-21-021332 · form4.xml · nonDerivative · entry 1

HAWKINS WILLIAM A · CIK 0001106508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,820

SEC source: 0001127602-21-021331 · form4.xml · nonDerivative · entry 1

Mantas Jesus B · CIK 0001777331 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,718

SEC source: 0001127602-21-021327 · form4.xml · nonDerivative · entry 1

JONES WILLIAM D /CA/ · CIK 0001228380 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775

SEC source: 0001127602-21-021266 · form4.xml · derivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504

Underlying: Common Stock · 251 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020.

SEC source: 0001127602-21-021266 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 871.348

F1 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.

SEC source: 0001127602-21-021266 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-019553 · form4.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,169.1121

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.

SEC source: 0001127602-21-019552 · form4.xml · nonDerivative · entry 1

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,919

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001127602-21-019402 · form4.xml · nonDerivative · entry 1

Posner Brian S · CIK 0001372455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001127602-21-007011 · form4.xml · derivative · entry 1

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,310

Underlying: Common Stock · 45,310 shares

Expires 2024-02-18

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).